Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Data from controlled clinical studies in patients with more advanced idiopathic pulmonary fibrosis (IPF) could inform clinical practice, but they are limited, since this sub-population is usually excluded from clinical trials. These exploratory post-hoc analyses of the open-label, long-term extension study RECAP (NCT00662038) aimed to assess the efficacy and safety of pirfenidone in patients with more advanced IPF. Patients were categorised according to the extent of lung function impairment at baseline: more advanced (percent predicted FVC <50% and/or DLco <35%) and less advanced (percent predicted FVC ≥50% and DLco ≥35%).Overall, 596 patients with baseline FVC and/or DLco values available were included in the analyses; 187 patients had more advanced disease, and 409 patients had less advanced disease. Mean percent predicted FVC declined throughout 180 weeks of treatment in both more and less advanced disease subgroups. Both subgroups exhibited a similar pattern of adverse events; however, adverse events related to IPF progression were experienced by a higher proportion of patients with more advanced versus less advanced disease. Discontinuation rates due to any reason, adverse events related to IPF progression, or deaths were each higher in the more advanced versus the less advanced disease subgroup.These analyses found that longer-term pirfenidone treatment resulted in a similar rate of lung function decline and safety profile in patients with more advanced versus less advanced IPF, and the data suggest that pirfenidone is efficacious, well tolerated, and a feasible treatment option in patients with more advanced IPF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Multiple systematic reviews and meta-analyses have also confirmed the efficacy of nintedanib in reducing the decline in FVC seen in IPF patients [27,28,31,43,44].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [43]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Self-citationPirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationClinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium
Nathan, S. D., Shlobin, O. A., Weir, N., Ahmad, S., Kaldjob, J. M., Battle, E., Sheridan, M. J., & du Bois, R. M. (2011) · Chest · doi:10.1378/chest.10-2572 · Cited by 369
Costabel, U., Albera, C., LANCASTER, L. H., Lin, C.-Y., Hormel, P., Hulter, H. N., & Noble, P. W. (2017) · Respiration · doi:10.1159/000479976 · Cited by 161
Self-citationGlaspole, I., Chapman, S. A., Cooper, W. A., Ellis, S. J., Goh, N. S. L., Hopkins, P. M.-A., Macansh, S., Mahar, A. M., Moodley, Y. P., Paul, E. M., et al. (2017) · Respirology · doi:10.1111/resp.12989 · Cited by 142
Wuyts, W. A., Kolb, M., Stowasser, S., Stansen, W., Huggins, J. T., & Raghu, G. (2016) · Lung · doi:10.1007/s00408-016-9912-1 · Cited by 119
Self-citation
Cited by
Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
Bonella, F., Spagnolo, P., & Ryerson, C. (2023) · Drugs · doi:10.1007/s40265-023-01950-0 · Cited by 182
“Although post hoc analyses have suggested that nintedanib [35] and pirfenidone [36] have a similar effect on FVC decline in IPF patients with more versus less severe functional impairment, patients with FVC 50% or with significant comorbidities such as lung cancer and cardiovascular disease,…”
BackgroundBehr, J., Nathan, S. D., Wuyts, W. A., Moğulkoç, N., Bouros, D. E., Antoniou, K. M., Guiot, J., Kramer, M. R., Kirchgaessler, K.-U., Bengus, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30356-8 · Cited by 150
Self-citationRegulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?
van Geffen, C., Deißler, A., Quante, M., Renz, H. E., Hartl, D., & Kolahian, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663203 · Cited by 88
Faverio, P., Bocchino, M., Caminati, A., Fumagalli, A., Gasbarra, M., Iovino, P., Petruzzi, A., Scalfi, L., Sebastiani, A., Stanziola, A. A., et al. (2020) · Nutrients · doi:10.3390/nu12041131 · Cited by 80
Management of Idiopathic Pulmonary Fibrosis
Pleasants, R. A., & Tighe, R. M. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019862497 · Cited by 70
“Data from the open-label INPULSIS-ON study of nintedanib and RECAP study of pirfenidone suggest that the efficacy and safety of these treatments are similar in patients with severe lung function impairment (FVC ≤50% predicted in INPULSIS-ON and FVC <50% and/or DLco <35% predicted in RECAP) as in those with less advanc…”
Metadata
- Authors
- Costabel, U., Albera, C., Glassberg, M. K., Lancaster, L. H., Wuyts, W. A., Petzinger, U., Gilberg, F., Kirchgaessler, K.-U., & Noble, P. W.
- Affiliations
- Ruhrlandklinik (DE)
- University of Turin (IT)
- University of Miami Health System (US)
- Vanderbilt University Medical Center (US)
- Universitair Ziekenhuis Leuven (BE)
- F. Hoffmann-La Roche AG (CH)
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Costabel, Ulrich
- ORCID
- Venue
- Respiratory Research
- Published
- 2019-03-12
- Volume
- 20
- Issue
- 1
- Pages
- 55-55
- ISSN
- 1465-9921 (ISSN-L)
- 1465-993X
- PMC
- PMC6416878
- OpenAlex
- W2939662940
- Cited by
- 43
- References
- 9
- Citations by year
- 2025: 2 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 10 · 2020: 16 · 2019: 3
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- Respiratory Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- F. Hoffmann-La Roche, Ltd. (.)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, advanced disease, lung function decline, forced vital capacity, diffusing capacity for carbon monoxide, disease progression, adverse events, treatment discontinuation, post hoc analysis
- MeSH terms
- Aged, Anti-Inflammatory Agents, Non-Steroidal, Female, Humans, Male, Middle Aged, Pyridones, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1186/s12931-019-1021-2
- The paper
- Costabel, U., Albera, C., Glassberg, M. K., Lancaster, L. H., Wuyts, W. A., Petzinger, U., Gilberg, F., Kirchgaessler, K.-U., & Noble, P. W. (2019). Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respiratory Research. https://doi.org/10.1186/s12931-019-1021-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.